Document Detail

Independent prognostic value of intravenous dipyridamole with technetium-99m sestamibi tomographic imaging in predicting cardiac events and cardiac-related hospital admissions.
MedLine Citation:
PMID:  7594033     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: This study sought to establish the prognostic value of intravenous dipyridamole technetium-99m (Tc-99m) sestamibi single-photon emission computed tomographic (SPECT) myocardial perfusion imaging. BACKGROUND: Optimal management of patients with coronary artery disease involves strategies designed to reduce the risk of myocardial infarction and cardiac death. The role of myocardial perfusion imaging using newer clinical techniques to determine risk and possible benefit from therapy has not been evaluated. METHODS: Myocardial imaging results were classified as normal or abnormal (fixed or reversible defects; small, moderate or large). Follow-up evaluation of all patients included the occurrence of cardiac death or nonfatal myocardial infarction and other cardiac-related hospital admissions. RESULTS: During a mean (+/- SD) follow-up period of 12.8 +/- 6.8 months in 512 patients, 25 had a cardiac event. Patients with abnormal perfusion had significantly more cardiac events than those with normal perfusion (22 vs. 3, p < 0.01). Patients with reversible defects had the highest event rates (8.6%), and those with normal study results had a very low event rate (1.4%). Large defects were strongly associated with more cardiac events and hospital admissions than either normal scan results or abnormal results showing small defects. CONCLUSIONS: Patients with normal study results or a small defect after intravenous dipyridamole Tc-99m sestamibi SPECT imaging had an excellent short-term prognosis. Those with abnormal results (reversible or large defect) had an increased risk of subsequent cardiac death, nonfatal myocardial infarction and other cardiac-related hospital admissions.
G V Heller; S D Herman; M I Travin; J I Baron; C Santos-Ocampo; J R McClellan
Related Documents :
9665223 - Risk stratification with pre-hospital discharge exercise technetium-99m sestamibi myoca...
14693323 - Prediction of outcome after percutaneous coronary intervention for the acute coronary s...
9839163 - Post-mortem examination after cardiac surgery.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  26     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1995 Nov 
Date Detail:
Created Date:  1995-12-05     Completed Date:  1995-12-05     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1202-8     Citation Subset:  AIM; IM    
Nuclear Cardiology Laboratory, Hartford Hospital, Connecticut 06102, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Dipyridamole / administration & dosage,  diagnostic use*
Heart Diseases / radionuclide imaging*
Injections, Intravenous
Middle Aged
Predictive Value of Tests
Prospective Studies
Technetium Tc 99m Sestamibi / diagnostic use*
Tomography, Emission-Computed
Vasodilator Agents / administration & dosage,  diagnostic use*
Reg. No./Substance:
0/Vasodilator Agents; 109581-73-9/Technetium Tc 99m Sestamibi; 58-32-2/Dipyridamole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Thallium-201 myocardial tomography with intravenous infusion of adenosine triphosphate in diagnosis ...
Next Document:  Noninvasive prediction of coronary atherosclerosis by quantification of coronary artery calcificatio...